Pharmidex hosts annual Japanese exchange students
November 3, 2015

Student visit from Meiji Pharmaceutical University (Japan) and the Department of Pharmacy, University of Hertfordshire (UK) to Pharmidex Facility.

Pharmidex has the pleasure of continuing to host Japanese exchange students.



Yoko Haraguchi and Soko Yoshino visited Pharmidex as part of their academic exchange program between Meiji Pharmaceutical University (Japan) and the Department of Pharmacy, University of Hertfordshire (UK). The Pharmidex team had the pleasure of welcoming a new set of students from Japan on a tour of our facilities and experiencing what it is like to work in SME within the Pharmaceutical sector in the European Union.


Business development manager Dr Martin Barrett was once again pleased to continue the company’s collaborations with Meji Pharmaceutical University and Department of Pharmacy, University of Hertfordshire, furthermore as a company we very much look forward to fostering closer links with all interested parties on mutually beneficial projects. Dr Nkiruka Umaru (Nikkie) of Department of Pharmacy, school of life and medical sciences at University of Hertfordshire also added that University of Hertfordshire is delighted that our Japanese visitors had the opportunity to learn more about the dynamic biotechnology SMEs in UK.

November 5, 2025
We’re excited to welcome Grace Horne as our new Bioanalytical Scientist! 🎉 Grace brings great enthusiasm and passion for science, and we’re confident she’ll make a fantastic contribution to our team. Welcome aboard, Grace, we’re thrilled to have you with us! 💜
November 4, 2025
We’re pleased to share that Janette Dalay Robertson , Business Development Manager at Pharmidex , will attend the DDW Turning Science into Business Symposium 2025 on Tuesday, 4th November, at the The Francis Crick Institute , London. Janette looks forward to connecting with industry leaders and exploring new collaboration opportunities.
November 3, 2025
We’re delighted to announce that Pharmidex will present our poster "Driving breakthroughs in Parkinson’s & neurodegeneration research” at the upcoming RSC BMCS meeting. With over 23 years of CNS expertise, we support biopharma partners in developing new therapies for Parkinson’s disease and tauopathies, through: 🔹 Parkinson’s & neurodegeneration models 🔹 Transgenic CNS lines (incl. 5xFAD) 🔹 Biomarker & BBB penetration studies Join us in Cambridge to explore how our GLP-accredited CNS platforms accelerate discovery and development.
More Posts